Popular Articles
Cellulite Cream

Endeavor Drug-Eluting Stent Is First To Receive CE Mark For Treating Acute Coronary Syndrome
Medtronic, Inc. (NYSE: MDT), announced that its Endeavor drug-eluting stent (DES) is the first and only coronary stent to have received CE (Conformité Européene) Mark approval for treating patients with acute coronary syndrome (ACS), which includes unstable angina and acute myocardial infarction (AMI), commonly known as heart attack.
generic viagra online
'SEE-ing' The Difference: Evaluation Shows $167 Million Investment Improves Community Mental Health System, But Many Still In Need
Can $167 million in provincial funding make a difference to Ontario"s community mental health system? According to the results from the Systems Enhancement Evaluation Initiative (SEEI), the answer is yes. Ontarians now have access to more appropriate community mental health services. But, the research also highlights the system"s limited res to serve all those in need.
News of the day
First High-Definition Endoscopic Ultrasound (EUS) Technology Enhances Diagnostic Procedures
Physicians can now provide potentially safer and more accurate diagnostic procedures with the first and only high-definition endoscopic ultrasound (EUS) needle technology. Cook Medical, the only full-line supplier of endoscopic medical devices, has designed a complete line of high-definition EUS biopsy needles that are up to three-times brighter than others on the market. With the addition of the 19 and 25 gage EchoTip® Ultra with High Definition Fine Needle Aspiration (HDFNA™) needles, the EchoTip Ultra HDFNA represents the next level of precision in EUS, an essential diagnostic tool that yields more accurate images of the gastrointestinal (GI) tract than traditional ultrasound and provides minimally invasive access to areas that are traditionally difficult to reach.
Public Health

ASGT 12th Annual Meeting: Incorporate Gene Therapy To Make Stem Cell Treatment Safer, More Effective

Gene therapy should be used in tandem with stem cell therapy to enhance the reliability of stem cells, provide an opportunity to limit adverse effects and increase treatment success, according to research presented at the American Society of Gene Therapy"s 12th Annual Meeting, May 30. "Stem cell therapy offers enormous potential to treat and even cure serious diseases. But wayward stem cells can turn into a runaway train without a conductor," said Ronald G. Crystal, MD, chief of the Division of Pulmonary and Critical Care Medicine at New York Presbyterian Hospital/Weill Cornell Medical Center. "This is an issue that can be dealt with and we have the technology to do that in the form of gene therapy." The challenges with stem cells are unique - once a transplant is performed, the cells go to work on their own, leaving the therapist without control of the therapy"s outcome. Gene therapy, however, provides a means for predetermining, and controlling, how the implanted stem cells will react in the patient. After implantation, stem cells multiply and differentiate into new types of cells. This ability is what gives them their unique potential as medical treatment. But problems arise when the cells differentiate incorrectly, multiply excessively, migrate to new areas of the body or form tumors. By modifying the genetic code of these cells prior to transplantation, researchers can program the cells to prevent adverse effects or self-destruct should they go awry. A couple of recent events have cast a new urgency on this research. In January, the Food and Drug Administration approved the first human trials using embryonic stem cells and, in March, the Obama administration reversed an earlier policy restricting federal funding for embryonic stem cell research. Scientists believe these steps will lead to accelerated development of stem cell therapies. Stem cells hold promise for treating a host of common diseases, including diabetes, Parkinson"s disease, cancer and others. The American Society of Gene Therapy (ASGT) 12th Annual Meeting is the world"s largest scientific meeting surrounding the latest developments in gene and cell therapy, attended by nearly 2,000 researchers from around the world and featuring 60 scientific presentations. ASGT


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):